| Literature DB >> 25944875 |
Gabriella Malfatto1, Sergio Caravita2, Alessia Giglio1, Jessica Rossi1, Giovanni B Perego1, Mario Facchini1, Gianfranco Parati2.
Abstract
BACKGROUND: In patients with chronic heart failure, abnormal ventilation at cardiopulmonary testing (expressed by minute ventilation-to-carbon dioxide production, or VE/VCO2 slope, and resting end-tidal CO2 pressure) may derive either from abnormal autonomic or chemoreflex regulation or from lung dysfunction induced by pulmonary congestion. The latter hypothesis is supported by measurement of pulmonary capillary wedge pressure, which cannot be obtained routinely but may be estimated noninvasively by measuring transthoracic conductance (thoracic fluid content 1/kΩ) with impedance cardiography. METHODS ANDEntities:
Keywords: abnormal ventilation; cardiopulmonary test; chronic heart failure; impedance cardiography; pulmonary congestion
Mesh:
Substances:
Year: 2015 PMID: 25944875 PMCID: PMC4599404 DOI: 10.1161/JAHA.114.001678
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Clinical Data of Patients Undergoing Both Studies
| Invasive Study (n=9) | Noninvasive Study (n=190) | |
|---|---|---|
| Age | 66±7 | 67± 3 |
| Sex, male/female | 8/1 | 151/39 |
| Ischemic/nonischemic | 6/3 | 135/55 |
| NYHA I | – | 18 |
| NYHA II | 2 | 81 |
| NYHA III | 7 | 91 |
| NYHA IV | – | – |
| SAP, mm Hg | 112±16 | 118±26 |
| DAP, mm Hg | 67±10 | 71±8 |
| HR, bpm | 66±12 | 68±10 |
| EF, % | 30±5 | 32±7 |
| PAP, mm Hg | 47±14 | 48±11 |
| Moderate to severe mitral regurgitation | 4 (48%) | 24 (46%) |
| BNP, pg/mL | 475.0±49.3 | 403.5±69.7 |
| Therapy (% of patients) | ||
| ACE inhibitors and/or ATII inhibitors | 100% | 85% |
| β-blockers | 72% | 84% |
| Amiodarone | 54% | 60% |
| Diuretics | 100% | 90% |
| Others (digoxin, ivabradine) | 2% | 6% |
| ICD and/or ICD+CRT | 72% | 69% |
Data are expressed as mean±1 SD except as noted. ACE indicates angiotensin-converting enzyme; ATII, angiotensin II; BNP indicates brain natriuretic peptide; CRT, cardiac resynchronization therapy; DAP, diastolic arterial pressure; EF, ejection fraction; HR, heart rate; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association classification; PAP, estimated pulmonary arterial pressure; SAP, systolic arterial pressure.
Cardiopulmonary Test and Invasive and Noninvasive Hemodynamics
| Invasive Study (n=9) | Noninvasive Study (n=190) | |
|---|---|---|
| Hemodynamic during cardiopulmonary test | ||
| CVP, cm H2O | 13.5±2.1 | NA |
| SVRI resting, dyn/s/cm−5/m2 | 2968.7±662.8 | NA |
| PAPs resting, mm Hg | 39.5±10.1 | NA |
| PCWP resting, mm Hg | 17.2±6.7 | NA |
| PCWP peak, mm Hg | 32.7±11.7 | NA |
| Stroke volume resting, mL | 53.6±7.1 | NA |
| Resting impedance cardiograhy | ||
| SVRI rest, dyn/s/cm−5/m2 | NA | 2062.1±874.7 |
| TFC, 1/kΩ | NA | 37.3±6.8 |
| Stroke volume resting, mL | NA | 70.1±21.7 |
| Cardiopulmonary test results | ||
| Peak VO2, mL/kg/min | 16.5±2.4 | 14.4±3.7 |
| Oxygen pulse, mL/beat | 10.3±1.9 | 10.5±3.2 |
| Resting PETCO2, mm Hg | 30.1±4.1 | 32.8±4.7 |
| VE/VCO2 slope | 37.4±5.2 | 36.5±5.8 |
| Functional classification, n (%) | ||
| Weber-Janicki class A | 0 (0) | 10 (5) |
| Weber-Janicki class B | 4 (44) | 54 (28) |
| Weber-Janicki class C | 5 (56) | 98 (52) |
| Weber-Janicki class D | 0 (0) | 28 (15) |
| Ventilatory classification, n (%) | ||
| Arena et al class 1 | 0 (0) | 15 (8) |
| Arena et al class 2 | 4 (44) | 84 (44) |
| Arena et al class 3 | 4 (44) | 80 (42) |
| Arena et al class 4 | 1 (12) | 11 (6) |
Data are expressed as mean±1 SD except as noted. CVP indicates central venous pressure; NA, not available; PAPs, pulmonary artery pressure systolic; PCWP, pulmonary capillary wedge pressure; PETCO2, end-tidal CO2 pressure; SVRI, systemic vascular resistances, indexed; TFC, transthoracic conductance; VE/VCO2, minute ventilation-to-carbon dioxide production; VO2, oxygen consumption per unit time.
P<0.02 vs resting.
Figure 1Relationship between VE/VCO2 slope and resting (A) and peak (B) pulmonary capillary wedge pressure (PCWP) during cardiopulmonary test in 9 patients undergoing hemodynamic study. VE/VCO2 indicates minute ventilation-to-carbon dioxide production.
Figure 2Relationship between resting PETCO2 and resting (A) and peak exercise (B) pulmonary capillary wedge pressure (PCWP) during cardiopulmonary test in 9 patients undergoing hemodynamic study before the test. PETCO2 indicates end-tidal CO2 pressure.
Figure 3Relationship between baseline transthoracic conductance (TFC) and VE/VCO2 slope at cardiopulmonary testing in 190 patients undergoing noninvasive hemodynamic evaluation before the test. VE/VCO2 indicates minute ventilation-to-carbon dioxide production.
Figure 4Relationship between baseline transthoracic conductance (TFC) and resting PETCO2 at cardiopulmonary testing in 190 patients undergoing noninvasive hemodynamic evaluation before the test. PETCO2 indicates end-tidal CO2 pressure.
Cardiopulmonary Test and Noninvasive Hemodynamics According to Functional and Ventilatory Classes
| Weber-Janicki classes | A (n=10) | B (n=54) | C (n=98) | D (n=28) |
|---|---|---|---|---|
| Peak VO2, mL/kg/min | 22.5±0.9 | 17.8±1.2 | 13.4±1.5 | 9.3±1.3 |
| Oxygen pulse, mL/beat | 14.7±3.3 | 12.5±3.1 | 10.0±2.7 | 8.2±2.7 |
| Resting PETCO2, mm Hg | 36.1±4.7 | 33.1±4.0 | 32.9±4.9 | 31.7±5.5 |
| VE/VCO2 slope | 31.8±3.9 | 35.4±4.2 | 36.9±3.2 | 38.9±6.9 |
| TFC, 1/KΩ | 36.0±2.9 | 36.7±5.2 | 37.8±3.1 | 39.3±9.2 |
| Stroke volume resting, mL | 85.5±17.8 | 68.0±3.6 | 70.6±23.3 | 70.4±16.9 |
Data are expressed as mean±1 SD. PETCO2, end-tidal CO2 pressure; TFC indicates transthoracic conductance;VE/VCO2, minute ventilation-to-carbon dioxide production; VO2, oxygen consumption per unit time.
P<0.05 Weber-Janicki class D vs Weber-Janicki class A (ANOVA with Bonferroni correction).
P<0.05 Arena et al class 4 vs either Arena et al class 1 or class 2 (ANOVA with Bonferroni correction).
P<0.05 each of the Arena et al classes compared with the others (ANOVA with Bonferroni correction).